Middle East Pharmaceutical Industries Company (TADAWUL:4016)
Saudi Arabia
· Delayed Price · Currency is SAR 120.90
+0.20 (0.17%)
Dec 4, 2025, 3:10 PM AST
TADAWUL:4016 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 458.96 | 394 | 338.44 | 302.66 | 287.22 | 301.66 |
| Revenue Growth (YoY) | 18.54% | 16.42% | 11.82% | 5.38% | -4.79% | - |
| Cost of Revenue | 174.55 | 151.59 | 134.74 | 119.21 | 113.47 | 126.25 |
| Gross Profit | 284.4 | 242.41 | 203.7 | 183.45 | 173.76 | 175.41 |
| Selling, General & Admin | 176.44 | 150 | 127.59 | 113.73 | 97.74 | 92.87 |
| Other Operating Expenses | -0.03 | -0.42 | 0.09 | 0.18 | -0.14 | 0.05 |
| Operating Expenses | 177.25 | 153.12 | 126.17 | 114.04 | 97.6 | 94.92 |
| Operating Income | 107.15 | 89.29 | 77.53 | 69.41 | 76.16 | 80.49 |
| Interest Expense | -3.64 | -3.67 | -5.75 | -4.73 | -1.87 | -1.2 |
| Currency Exchange Gain (Loss) | -0.04 | -0.04 | -0.47 | 0.27 | - | - |
| Other Non Operating Income (Expenses) | - | - | - | - | -1.08 | -1.48 |
| EBT Excluding Unusual Items | 103.47 | 85.58 | 71.31 | 64.95 | 73.22 | 77.81 |
| Gain (Loss) on Sale of Investments | - | - | - | - | -2.76 | - |
| Gain (Loss) on Sale of Assets | 0.12 | 0.12 | 0.13 | 0.08 | - | - |
| Pretax Income | 104.24 | 86.35 | 71.44 | 65.02 | 70.46 | 77.81 |
| Income Tax Expense | 6.95 | 6.5 | 5.61 | 5.57 | 4.18 | 5 |
| Net Income | 97.29 | 79.85 | 65.83 | 59.45 | 66.28 | 72.81 |
| Net Income to Common | 97.29 | 79.85 | 65.83 | 59.45 | 66.28 | 72.81 |
| Net Income Growth | 20.95% | 21.30% | 10.72% | -10.31% | -8.97% | - |
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 |
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 |
| EPS (Basic) | 4.86 | 3.99 | 3.29 | 2.97 | 3.31 | 3.64 |
| EPS (Diluted) | 4.86 | 3.99 | 3.29 | 2.97 | 3.31 | 3.64 |
| EPS Growth | 20.95% | 21.30% | 10.72% | -10.31% | -8.97% | - |
| Free Cash Flow | 84.07 | 24.13 | 71.82 | 58.99 | 25.28 | 11.42 |
| Free Cash Flow Per Share | 4.20 | 1.21 | 3.59 | 2.95 | 1.26 | 0.57 |
| Dividend Per Share | 2.350 | 2.000 | - | - | - | - |
| Gross Margin | 61.97% | 61.52% | 60.19% | 60.61% | 60.50% | 58.15% |
| Operating Margin | 23.35% | 22.66% | 22.91% | 22.93% | 26.52% | 26.68% |
| Profit Margin | 21.20% | 20.27% | 19.45% | 19.64% | 23.08% | 24.14% |
| Free Cash Flow Margin | 18.32% | 6.12% | 21.22% | 19.49% | 8.80% | 3.79% |
| EBITDA | 118.95 | 99.08 | 85.14 | 76.25 | 82.86 | 87.19 |
| EBITDA Margin | 25.92% | 25.15% | 25.16% | 25.19% | 28.85% | 28.90% |
| D&A For EBITDA | 11.8 | 9.8 | 7.61 | 6.84 | 6.7 | 6.69 |
| EBIT | 107.15 | 89.29 | 77.53 | 69.41 | 76.16 | 80.49 |
| EBIT Margin | 23.35% | 22.66% | 22.91% | 22.93% | 26.52% | 26.68% |
| Effective Tax Rate | 6.66% | 7.53% | 7.85% | 8.57% | 5.93% | 6.43% |
Source: S&P Capital IQ. Standard template. Financial Sources.